Eltrombopag before Procedures in Patients with Cirrhosis and Thrombocytopenia | Zendy

Nezam H. Afdhal | Zendy; Edoardo G. Giannini | Zendy; Ghias Un Nabi Tayyab | Zendy; Aftab Mohsin | Zendy; JinWoo Lee | Zendy; Angelo Andriulli | Zendy; Lennox J. Jeffers | Zendy; John G. McHutchison | Zendy; PeiJer Chen | Zendy; Kwang–Hyub Han | Zendy; Fiona Campbell | Zendy; Denise Hyde | Zendy; Andrés Brainsky | Zendy; Dickens Theodore | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Eltrombopag before Procedures in Patients with Cirrhosis and Thrombocytopenia

Author(s) -

Nezam H. Afdhal,

Edoardo G. Giannini,

Ghias Un Nabi Tayyab,

Aftab Mohsin,

JinWoo Lee,

Angelo Andriulli,

Lennox J. Jeffers,

John G. McHutchison,

PeiJer Chen,

Kwang–Hyub Han,

Fiona Campbell,

Denise Hyde,

Andrés Brainsky,

Dickens Theodore

Publication year - 2012

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1110709

Subject(s) - eltrombopag , medicine , thrombopoietin receptor , thrombopoietin , cirrhosis , platelet , chronic liver disease , gastroenterology , agonist , surgery , receptor , immune thrombocytopenia , haematopoiesis , genetics , stem cell , biology

Eltrombopag is an oral thrombopoietin-receptor agonist. This study evaluated the efficacy of eltrombopag for increasing platelet counts and reducing the need for platelet transfusions in patients with thrombocytopenia and chronic liver disease who are undergoing an elective invasive procedure.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research